SMMT
The sequel got better ratings
Summit Therapeutics shareholders got a nice Monday caffeine shot after partner Akeso said its Phase 3 HARMONi-2 trial kept making ivonescimab look like a serious problem for pembrolizumab. In the intention-to-treat population, the drug posted a median overall survival of 30.8 months versus 22.6 months for Keytruda’s active ingredient, which is the sort of gap that makes biotech investors sit up a little straighter.
Why the market cared
This wasn’t just a one-off “nice data, everyone clap” moment. The company said the result translated into a 27% reduction in the risk of death after a median 36-month follow-up, with 234 survival events. Even better for the bulls, the benefit showed up across prespecified subgroups, including a 42% mortality reduction in patients with PD-L1 tumor proportion scores of 50% or higher.
The fine print, because biotech loves fine print
The data also looked decent in squamous and non-squamous patients, and the safety profile didn’t flash any obvious bleeding scare even in tougher-to-treat squamous cases. That matters because investors are not just buying “drug works” — they’re buying “drug works and regulators/oncologists don’t immediately side-eye it.”
Big picture
Summit is still riding on its partner’s china-first, global-ambition story, but every strong readout makes ivonescimab look less like a niche hopeful and more like a real challenger in a giant lung-cancer market. If the market keeps believing the story, SMMT doesn’t just get a bounce — it gets a very loud argument for why it deserves one.